MedTrace Logo

Response Variability to Exercise

NCT05496751 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-03-20

No results posted yet for this study

Summary

In this proposal, the investigators challenge the assumption that following the physical activity guidelines implies benefit for ALL adults, and that if benefit is not achieved in response to first line therapy, it will be by simply exercising more. Thus, for improving cardiorespiratory fitness and cardiometabolic risk factors, unanswered questions include: 1) To what extent, regardless of increasing exercise intensity or amount, is exercise not associated with benefit? Demonstration of a resistance to benefit through exercise in a substantial number of adults would be a novel and important finding, would counter the assumptions of many if not most health care practitioners, and could have immediate and direct application in all health care settings. 2) To what extent will non-responders to first line therapy (150 min/wk) be required to increase exercise intensity or amount to achieve benefit? 3) To what extent will failure to improve CRF segregate (be associate with) with cardiometabolic risk factors? The investigators propose that adults who remain exercise resistant for improvement in CRF and cardiometabolic risk despite increasing amount or intensity are at high risk of metabolic disease and consequently, are candidates for alternative treatment strategies.

Conditions

  • Exercise
  • Cardiorespiratory Fitness

Interventions

BEHAVIORAL

Low amount, low intensity exercise

Participants will exercise under supervision. Exercise dose will vary by amount and intensity

BEHAVIORAL

Low amount, high intensity exercise

Participants will exercise under supervision. Exercise dose will vary by amount and intensity

BEHAVIORAL

High amount, high intensity exercise

Participants will exercise under supervision. Exercise dose will vary by amount and intensity

Sponsors & Collaborators

  • Robert Ross, PhD

    lead OTHER

Principal Investigators

  • Robert Ross, PhD · Queen's University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2025-09-30
Completion
2025-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05496751 on ClinicalTrials.gov